AL amyloidosis, a curable disease?

Amyloid

Volumn 9, Issue 3, 2002, Pages 203-206

  Seldin, David C ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE; ALKYLATING AGENT;

AMYLOIDOSIS; DRUG MEGADOSE; EDITORIAL; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; MORTALITY; MULTIPLE MYELOMA; PATIENT SELECTION; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; NOTE;

AMYLOIDOSIS; ANTINEOPLASTIC AGENTS, ALKYLATING; HUMANS; MELPHALAN; STEM CELL TRANSPLANTATION;

EID: 0036750972     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120209114825     Document Type: Editorial

References (16)

1. Cathcart ES and Cohen AS (1966). The relation between isolated human amyloid fibrils and human gamma- globulin and its subunits. J Immunol 96, 239-244
2. Glenner GG, Terry W, Harada M, Isersky C and Page D (1971). Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 172, 1150-1151
3. Perfetti V, Coluccia AM, Intini D, Malgeri U, Vignarelli MC, Casarini S, Merlini G and Neri A (2001). Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol 158, 1599-1603.
4. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, Jones LA and Cohen AS (1996). Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100, 290-298
5. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ and Therneau TM (1997). A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336, 1202-1207
6. Majolino I, Marceno R, Pecoraro G, Scime R, Vasta S, Liberti G, Rizzo A, Indovina A and Caronia F (1993). Autologous stem cell transplantation in amyloidosis AL. Bone Marrow Transplant 11, 85
7. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH and Skinner M (1996). Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 88, 2801-2806
8. Gillmore JD, Apperley JF, Craddock C, Madhoo S, Pepys MB and Hawkins PN (1998). High dose melphalan and stem cell rescue for AL amyloidosis. In Kyle RA, M.A. G, eds. Amyloid and Amyloidosis, 102-104. (Pearl River, NY: Parthenon Publishing)
9. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, Hermine O, Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N and Harousseau JL (1998). Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 101, 766-769
10. Saba N, Sutton D, Ross H, Siu S, Crump R, Keating A and Stewart A (1999). High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 24, 853-855
11. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'Hara C, Arkin CF, Wright DG and Skinner M (1998). Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 91, 3662-3670
12. Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Cerda S, Berk JL, Dember LM, Falk R, Finn K, Skinner M and Vosburgh E (1999). Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 104, 553-559
13. Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A, Kyle RA and Litzow MR (2000). Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 26, 963-969
14. Comenzo RL and Gertz MA (2002). Autologous stem cell transplantation for primary, systemic amyloidosis. Blood 99, 4276-4282
15. Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K and Skinner M (2001). An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28, 637-642
16. Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA and Gertz MA (2001). Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19, 3350-3356